Culture	B-Reagent
of	O
the	O
severe	B-Modifier
acute	I-Modifier
respiratory	I-Modifier
syndrome	I-Modifier
coronavirus	B-Reagent
2	I-Reagent
(	O
SARS-CoV-2	B-Reagent
;	O
f.2019-nCoV	O
)	O

Cell	B-Location
culture	I-Location
tubes	I-Location
were	O
moved	B-Action
from	O
the	O
37	B-Temperature
C	I-Temperature
incubator	B-Device
to	O
a	O
Class	B-Location
II	I-Location
Biosafety	I-Location
cabinet	I-Location
,	O
within	O
a	O
PC3	B-Location
laboratory	I-Location
environment	I-Location
.	O

Growth	B-Reagent
medium	I-Reagent
from	O
previously	B-Modifier
prepared	B-Action
Vero	B-Location
E6	I-Location
tubes	I-Location
was	O
discarded	B-Action
to	O
waste	B-Location
.	O

Clinical	B-Reagent
samples	I-Reagent
were	O
prepared	B-Action
by	O
diluting	B-Action
in	O
Opti-Mem	B-Modifier
reduced	I-Modifier
serum	B-Reagent
growth	I-Reagent
medium	I-Reagent
without	O
foetal	B-Reagent
bovine	I-Reagent
serum	I-Reagent
(	O
FBS	B-Reagent
)	O
and	O
filtering	B-Action
through	O
a	O
0.2	B-Concentration
M	I-Concentration
,	O
13	B-Size
mm	I-Size
Acrodisc	B-Device
filter	I-Device
(	O
Bio-Strategy	O
Laboratory	O
Products	O
,	O
Australia	O
)	O
.	O

150-200	B-Amount
L	I-Amount
of	O
filtered	B-Modifier
patient	B-Reagent
material	I-Reagent
was	O
inoculated	B-Action
onto	O
separate	B-Modifier
confluent	I-Modifier
cell	B-Reagent
monolayers	I-Reagent
along	O
with	O
a	O
negative	B-Location
control	I-Location
tube	I-Location
(	O
150-200	B-Amount
L	I-Amount
of	O
Opti-Mem	B-Reagent
alone	O
)	O
.	O

NOTE	O
:	O
Fresh	B-Modifier
specimens	B-Reagent
are	O
best	O
for	O
succesful	B-Modifier
viral	B-Reagent
culture	I-Reagent
.	O

Samples	B-Reagent
were	O
absorbed	B-Action
onto	O
cells	B-Reagent
by	O
incubating	B-Action
tubes	B-Location
for	O
1	B-Time
hr	I-Time
at	O
37	B-Temperature
C	I-Temperature
before	O
cultures	B-Reagent
were	O
re-fed	B-Action
with	O
2	B-Amount
mL	I-Amount
of	O
pre-warmed	B-Modifier
(	O
37	B-Temperature
C	I-Temperature
)	O
Opti-Mem	B-Modifier
reduced	I-Modifier
serum	B-Reagent
growth	I-Reagent
medium	I-Reagent
.	O

NOTE	O
:	O
It	O
can	O
be	O
informative	O
to	O
collect	B-Action
a	O
200	B-Amount
L	I-Amount
sample	B-Reagent
at	O
this	O
point	O
as	O
a	O
Day	B-Time
0	I-Time
value	O
to	O
test	B-Action
alongside	O
other	O
culture	B-Reagent
samples	I-Reagent
from	O
Day	B-Time
2	I-Time
onwards	O
.	O

Cultures	B-Reagent
were	O
incubated	B-Action
for	O
2-7	B-Time
days	I-Time
until	O
signs	O
of	O
cytopathic	B-Reagent
effect	I-Reagent
(	O
CPE	B-Reagent
)	O
was	O
observed	B-Action
.	O

In	O
our	O
hands	O
,	O
cultures	B-Reagent
that	O
were	O
inoculated	B-Action
with	O
patient	B-Reagent
sample	I-Reagent
extracts	I-Reagent
which	O
,	O
at	O
original	B-Modifier
testing	B-Action
produced	O
CTs	B-Measure-Type
of	O
approximately	B-Modifier
20	B-Generic-Measure
cycles	I-Generic-Measure
,	O
developed	B-Action
signs	O
of	O
CPE	B-Reagent
within	O
3	B-Time
days	I-Time
post-inoculation	B-Modifier
.	O

In	O
the	O
event	O
low-levels	B-Generic-Measure
of	O
the	O
virus	B-Reagent
were	O
not	O
detected	B-Action
by	O
observation	B-Method
of	O
CPE	B-Reagent
in	O
the	O
first	O
isolation	B-Method
attempt	O
,	O
negative	B-Reagent
cell	I-Reagent
culture	I-Reagent
supernatants	I-Reagent
should	O
be	O
further	O
passaged	B-Action
onto	O
fresh	B-Modifier
Vero	B-Reagent
E6	I-Reagent
monolayers	I-Reagent
up	B-Modifier
to	I-Modifier
3	B-Numerical
times	I-Numerical
with	O
testing	B-Action
as	O
described	O
in	O
Step	O
6	O
.	O

A	O
cell	B-Reagent
culture	I-Reagent
is	O
suspected	O
of	O
hosting	B-Action
virus	B-Reagent
replication	I-Reagent
based	O
on	O
the	O
presence	O
of	O
CPE	B-Reagent
including	O
damage	O
to	O
the	O
monolayer	B-Reagent
,	O
cell-clearing	B-Modifier
and	O
morphological	B-Modifier
changes	O
.	O

Suspected	B-Modifier
cultures	B-Reagent
were	O
further	O
confirmed	B-Action
using	O
the	O
Corman	B-Method
et	I-Method
al	I-Method
.	O
E	B-Method
E	I-Method
and	I-Method
Northill	I-Method
et	I-Method
al	I-Method
.	O

ORF1ab	B-Modifier
ORF1ab	I-Modifier
novel	B-Reagent
coronavirus	I-Reagent
reverse-transcription	B-Method
real-time	I-Method
polymerase	I-Method
chain	I-Method
reaction	I-Method
(	O
RT-rPCRs	B-Method
)	O
tests	O
.	O

Samples	B-Reagent
taken	B-Action
from	O
a	O
suspected	B-Modifier
culture	B-Reagent
are	O
expected	O
to	O
contain	O
levels	O
of	O
virus	B-Reagent
that	O
exceed	O
those	O
present	O
in	O
the	O
original	B-Modifier
clinical	B-Reagent
sample	I-Reagent
so	O
we	O
would	O
expect	O
to	O
see	O
CT	B-Measure-Type
values	O
lower	B-Modifier
than	I-Modifier
those	B-Mention
obtained	B-Action
from	O
testing	B-Action
the	O
original	B-Modifier
clinical	B-Reagent
sample	I-Reagent
extract	I-Reagent
by	O
RT-rPCRs	B-Method
.	O

SLOW	B-Modifier
CULTURES	B-Reagent
:	O
If	O
the	O
CT	B-Measure-Type
value	O
from	O
an	O
extract	B-Reagent
of	O
the	O
first	B-Reagent
passage	I-Reagent
of	O
a	O
SARS-CoV-2	B-Reagent
culture	I-Reagent
is	O
the	O
same	B-Modifier
or	O
higher	B-Modifier
(	O
suggesting	B-Action
a	O
lower	B-Modifier
viral	B-Measure-Type
load	I-Measure-Type
)	O
than	O
the	O
CT	B-Measure-Type
value	O
from	O
the	O
RT-rPCR	B-Method
of	O
the	O
original	B-Modifier
clinical	B-Reagent
sample	I-Reagent
,	O
further	O
investigation	B-Method
will	O
be	O
required	O
to	O
ensure	B-Action
the	O
culture	B-Reagent
has	O
biologically	B-Modifier
amplified	I-Modifier
virus	B-Reagent
.	O

Consideration	O
should	O
be	O
given	O
to	O
whether	O
such	O
a	O
result	O
is	O
due	O
to	O
the	O
detection	B-Method
of	O
viral	B-Reagent
remnants	I-Reagent
from	O
the	O
inoculum	B-Reagent
rather	O
than	O
virus	B-Method
amplification	I-Method
.	O



